Verily
Most Read
New diabetes tech is coming. But will it make much difference?
Scientist using big data against heart disease wins $75 million award
Pharmalot, Pharmalittle: Teva expects FDA to speed review of its generic EpiPen
Q&A: Glaxo exec says bioelectronics venture with Verily is ‘not science fiction’
Google spinoff teams with pharma giant to treat disease by zapping nerves
Top exec defends Google biotech spinoff, promises ‘amazing’ breakthroughs
